IP Strategies for Health Sciences Startups

IP Strategies for Health Sciences Startups

Speaking Engagement
Biotech and medical device companies are heavily dependent on intellectual property rights, particularly those developing diagnostic, therapeutic or invasive products. The complexity of the technology and rapidly evolving legal landscape make the availability, validity and enforceability of biotech patents highly uncertain. This session, led by Michael Twomey, a patent attorney and partner at WilmerHale, will explore some of the basic IP questions facing health sciences startups.

Read More About the Event